Ionis Pharmaceuticals, Inc. (IONS)
| Market Cap | 6.55B -44.5% |
| Revenue (ttm) | 874.09M -7.4% |
| Net Income | -565.17M |
| EPS | -3.46 |
| Shares Out | 166.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,911,837 |
| Open | 39.02 |
| Previous Close | 38.80 |
| Day's Range | 38.53 - 40.00 |
| 52-Week Range | 38.31 - 86.74 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 84.13 (+113.42%) |
| Earnings Date | Nov 9, 2026 |
About IONS
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ... [Read more]
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for IONS stock is "Buy." The 12-month stock price target is $84.13, which is an increase of 113.42% from the latest price.
News
Ionis to hold third quarter 2026 financial results webcast
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Monday, November 9 at 9:00 a.m. Eastern Time to discuss its third quar...
Roche says Sefaxersen trial shows meaningful reduction in proteinuria
Ionis Pharmaceuticals (IONS) partner Roche (RHHBY) announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy receiving optimized ...
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Roche announced today late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults wi...
Ionis ranked #1 on Science's Top Employers list
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the company was named the top employer to work for by Science in its annual Top Employers survey of t...
Ionis treatment of Dravet syndrome granted FDA orphan status
Ionis Pharmaceuticals (IONS) was granted FDA orphan designation for a treatment of Dravet syndrome, according to a post on the agency’s website.
5-star BMO analyst upgrades Ionis ahead of Q3 report
BMO Capital analyst David Lebowitz upgraded Ionis Pharmaceuticals (IONS) to Outperform from Market Perform with a price target of $66, up from $54, ahead of the Q3 report. The firm…
Ionis Pharmaceuticals upgraded to Outperform from Market Perform at BMO Capital
BMO Capital upgraded Ionis Pharmaceuticals (IONS) to Outperform from Market Perform with a price target of $66, up from $54.
3 Healthcare Stocks with Strong Buy Ratings and Double-Digit Upside
BioMarin Pharmaceutical ($BMRN), Boston Scientific ($BSX), and Ionis Pharmaceuticals ($IONS) are three healthcare stocks with Strong Buy ratings and double-digit upside, according to TipRanks. Leading...
Ionis Pharmaceuticals recent selloff overdone, says Citi
Citi analyst Eric Joseph views the recent pullback in shares of Ionis Pharmaceuticals (IONS) as overdone. The firm says a potentially soft initial quarter post the severe hypertriglyceridemia label ex...
Ionis Pharmaceuticals partner GSK announces FDA approval of Hibsago
Ionis Pharmaceuticals (IONS) partner GSK (GSK) announced that the FDA has approved Hibsago for the treatment of chronic hepatitis B, or CHB, virus infection in combination with nucleoside analogue rev...
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the t...
Ionis Pharmaceuticals price target lowered to $79 from $84 at Raymond James
Raymond James lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $79 from $84 and keeps an Outperform rating on the shares. Ionis maintained $100M-$110M FY26 Tryngolza guidance despite...
Ionis Pharmaceuticals says CHMP adopts positive opinion on tryngolza
Ionis Pharmaceuticals (IONS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the indication extension for...
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...
Ionis Pharmaceuticals upgraded to Buy from Neutral at UBS
UBS upgraded Ionis Pharmaceuticals (IONS) to Buy from Neutral with a price target of $88, up from $46. The firm is bullish on the company’s lead drug, Tryngolza, currently launching…
Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluat...
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Otsuka Pharmaceutical and Ionis Pharmaceuticals said on Tuesday their experimental drug met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosi...
Ionis announces Phase 3 FUSION study of ulefnersen met primary endpoint
Ionis Pharmaceuticals (IONS) and Otsuka (OTSKY) Pharmaceutical Development & Commercialization announced topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-tar...
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ionis Pharmaceuticals, Inc. today announced positive...
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive topline results from the Phase 3...
Ionis Pharmaceuticals price target lowered to $70 from $76 at JPMorgan
JPMorgan analyst Jessica Fye lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $76 and keeps an Overweight rating on the shares. The firm says the investment…
Cathie Wood’s ARK Investment buys 100K shares of Ionis Pharmaceuticals today
20:27 EDT Cathie Wood’s ARK Investment buys 100K shares of Ionis Pharmaceuticals (IONS) today
Ionis Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Two 2026 FDA approvals are secured, with a third expected in October; TRYNGOLZA launch activity and payer coverage are developing toward a $3B+ U.S. peak-sales goal. Pipeline milestones include Angelman data in H2 2026 and potential ION775 phase III entry in 2027.
Ionis Pharmaceuticals price target lowered to $80 from $89 at Guggenheim
Guggenheim lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $80 from $89 and keeps a Buy rating on the shares. The firm’s “quick poll” of 30 U.S. cardiologists…
Ionis Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
Multiple FDA approvals and strong launch momentum for new therapies highlight a year of strategic success. Key programs in sHTG, HAE, and HBV are advancing, while competitive positioning and pipeline innovation remain priorities.